Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026.

Could it be New Zealand’s Largest Class Action? A potential landmark consumer rights case alleges Johnson & Johnson sold New Zealanders decongestants containing a “useless” ingredient for nearly 20 ...

CAPLYTA net product sales grew to $199.2 million, representing a 51%increase over the same period in 2023Full year 2024 ...

Supernus Pharmaceutical’s stock declined following the release of disappointing Phase IIb trial results for SPN-820, an ...

Before Sunday's Super Bowl LIX matchup, Fox Sports aired a special feature highlighting the career of legendary NFL coach Jimmy Johnson. The feature utilized artificial intelligence to create ...

Clinical depression is a more severe type of depression, also called major depressive disorder (MDD). While exercise can help improve your symptoms, you will usually need medication and therapy to ...

Half of the study group met criteria for AUD in the past year and were evenly divided in terms of those who had or had not experienced a major depressive disorder in the past year. Individuals who ...

AUSTIN -- Texas Longhorns guard Tre Johnson is in the final running for a notable award amid a memorable freshman season on the Forty Acres. Johnson is one of 10 finalists for the Jerry West Award ...

Johnson & Johnson (NYSE: JNJ) is one of the world's largest and most prominent healthcare leaders. If investing in a company came down to size, the stock would be a no-brainer buy. However ...

It’s nearly a year and a half since Johnson & Johnson split off its consumer ... In 2024 we received 27 approvals across major markets for our innovative medicines and we launched more than ...

Johnson & Johnson (NYSE: JNJ) has a diverse healthcare business, and investors often look to it as a safe dividend stock to invest in for the long term. One area where it has been lacking, however ...